MMP9 and lung cancer: The integrated hybrid nanovesicle possesses unique and desirable features, including extended circulation half-life, effective homogeneous lung cancer-targeting ability, excellent biocompatibility, high tumor accumulation, MMP-9-activated tumor cell penetration, pH-triggered membrane disruption, and redox-triggered DTX and siRNA release.